Episode 2: Asthma

For today’s episode we will be reviewing three articles about asthma from the May-June 2019 issue of Allergy Watch: Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. https://www.ncbi.nlm.nih.gov/pubmed/30217529 Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. https://www.ncbi.nlm.nih.gov/pubmed/30205189 Indirect Treatment Comparisons and Biologics https://www.ncbi.nlm.nih.gov/pubmed/30612667 Endotypes of severe allergic asthma patients who clinically benefit from anti?IgE therapy https://www.ncbi.nlm.nih.gov/pubmed/30107059/ Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma https://www.ncbi.nlm.nih.gov/pubmed/29301922 Please give us feedback, corrections, and suggestions! Email feedback to: [email protected] ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from Astra Zenica. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire Research: Aimmune, DBV, Shire, Regeneron.